Sopixil (Spray, Drops) Instructions for Use
ATC Code
R01AA07 (Xylometazoline)
Active Substance
Xylometazoline (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Vasoconstrictor drug for topical use in ENT practice
Pharmacotherapeutic Group
Decongestant – vasoconstrictor (alpha-adrenomimetic)
Pharmacological Action
Vasoconstrictor agent for topical use in ENT practice. Alpha-adrenomimetic. When applied to the mucous membranes, it causes constriction of the blood vessels of the nasal mucosa, thereby eliminating swelling and hyperemia of the nasal mucosa, and restores the patency of the nasal passages. In rhinitis, it facilitates nasal breathing.
Pharmacokinetics
When applied topically, it is practically not absorbed; plasma concentrations are so low that they cannot be determined by modern analytical methods.
Indications
To reduce swelling of the nasopharyngeal mucosa and discharge in acute allergic rhinitis, acute respiratory infections with symptoms of rhinitis, sinusitis, hay fever, otitis media; preparation of the patient for diagnostic procedures in the nasal passages.
ICD codes
| ICD-10 code | Indication |
| H66 | Suppurative and unspecified otitis media |
| J00 | Acute nasopharyngitis (common cold) |
| J01 | Acute sinusitis |
| J06.9 | Acute upper respiratory infection, unspecified |
| J30.1 | Allergic rhinitis due to pollen |
| J30.3 | Other allergic rhinitis (perennial allergic rhinitis) |
| J32 | Chronic sinusitis |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| ICD-11 code | Indication |
| AA9Z | Unspecified suppurative otitis media |
| CA00 | Acute nasopharyngitis |
| CA01 | Acute rhinosinusitis |
| CA07.0 | Acute upper respiratory tract infection of unspecified site |
| CA08.00 | Allergic rhinitis due to pollen |
| CA08.03 | Other allergic rhinitis |
| CA0A.Z | Chronic rhinosinusitis, unspecified |
| QB9A | Preparatory procedures for subsequent treatment |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer intranasally. The dose depends on the dosage form and the age of the patient.
For the 0.05% solution (drops): Adults and children over 6 years old administer 1-2 drops into each nostril. For children aged 2 to 6 years, administer 1 drop into each nostril. Use no more than 3 times per day.
For the 0.1% solution (spray or drops): Use only in adults and children over 6 years old. Administer 1 injection into each nostril or 1-2 drops into each nostril. Use no more than 3 times per day.
For the 0.05% nasal spray: Use in children aged 2 to 6 years. Administer 1 injection into each nostril. Use no more than 3 times per day.
Limit the duration of continuous use to 3-5 days, and do not exceed 7 days. A doctor’s consultation is required for longer use.
Before use, clear the nasal passages. For spray, hold the bottle upright and keep your head straight. For drops, tilt your head slightly back.
Avoid exceeding the recommended dosage and frequency of administration to prevent systemic effects and medication-induced rhinitis.
Adverse Reactions
Immune system disorders uncommon – hypersensitivity reactions (angioedema, skin rash, itching).
Gastrointestinal disorders rare – nausea, vomiting.
Nervous system disorders: rare – headache; very rare – insomnia, anxiety, fatigue, hallucinations and convulsions (mainly in children).
Eye disorders very rare – blurred vision.
Cardiac and vascular disorders rare – palpitations, increased blood pressure, tachycardia; very rare – arrhythmia.
Local reactions common – irritation and/or dryness of the nasopharyngeal mucosa, burning and paresthesia of the nasal mucosa, sneezing, hypersecretion of the nasal mucosa; uncommon – swelling of the nasal mucosa, nosebleeds, withdrawal syndrome. Increased swelling of the nasal mucosa (reactive hyperemia) is possible.
Contraindications
Hypersensitivity to xylometazoline; atrophic rhinitis, thyrotoxicosis; inflammatory diseases of the skin or mucous membrane of the nasal vestibule; condition after transsphenoidal hypophysectomy; patients with severe cardiovascular diseases (e.g., coronary artery disease, angina pectoris, tachycardia, arterial hypertension, severe atherosclerosis); patients with a history of surgical interventions on the meninges; patients receiving MAO inhibitors or other drugs that can cause increased blood pressure; patients with increased intraocular pressure, especially angle-closure glaucoma; during therapy with tricyclic and tetracyclic antidepressants, other topical vasoconstrictors (decongestants); pregnancy; pediatric age – depending on the dosage form.
With caution patients with hypersensitivity to adrenomimetics, accompanied by symptoms of insomnia, dizziness, arrhythmia, tremor, increased blood pressure; patients with pheochromocytoma, porphyria; patients with endocrine diseases (e.g., hyperthyroidism, diabetes mellitus); patients with prostatic hyperplasia; during lactation (breastfeeding).
Use in Pregnancy and Lactation
Contraindicated for use during pregnancy. During lactation, use is possible only as prescribed by a doctor, after a thorough assessment of the benefit-risk ratio for the mother and the potential risk to the child. Exceeding the recommended doses is not allowed.
Pediatric Use
Use in children is possible according to indications, in age-appropriate recommended doses and dosage forms. It is necessary to strictly follow the instructions in the xylometazoline drug leaflets regarding contraindications for the use of specific xylometazoline dosage forms in children of different ages. Recommended doses should not be exceeded in children.
Geriatric Use
Recommended doses should not be exceeded in elderly patients.
Special Precautions
Long-term use (more than 7 days) and overdose of sympathomimetics with a decongestant effect can lead to reactive hyperemia of the nasal mucosa. As a result, nasal breathing difficulty occurs, which leads to the patient starting to use xylometazoline repeatedly or even constantly. This can lead to chronic swelling (medication-induced rhinitis), and ultimately even to atrophy of the nasal mucosa (ozena).
In milder cases, to improve the patient’s condition, it is initially possible to stop the administration of the sympathomimetic into one nostril, and after the complaints decrease, continue to administer it into the other nostril, in order to at least partially ensure nasal breathing.
Recommended doses should not be exceeded, especially in children and elderly patients.
Effect on ability to drive vehicles and operate machinery
During long-term treatment or when using xylometazoline in higher doses, the possibility of its systemic action cannot be excluded. In case of systemic side effects, it is necessary to refrain from driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
Drug Interactions
Enhancement of the systemic action of xylometazoline is possible with simultaneous use of MAO inhibitors and tricyclic antidepressants. Simultaneous use of xylometazoline with tetracyclic antidepressants, other topical vasoconstrictors (decongestants), as well as other drugs that increase blood pressure is incompatible.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Nasal drops 0.1%: 10 ml dropper bottle
Nasal drops 0.05%: 10 ml dropper bottle
Marketing Authorization Holder
Usolye-Sibirskiy Chemical and Pharmaceutical Plant, JSC (Russia)
Dosage Forms
| Sopixil | Nasal drops 0.1%: 10 ml dropper bottle | |
| Nasal drops 0.05%: 10 ml dropper bottle |
Dosage Form, Packaging, and Composition
Nasal drops as a colorless, clear or light yellow liquid.
| 1 ml | |
| Xylometazoline hydrochloride | 1 mg |
Excipients : benzalkonium chloride – 0.15 mg, disodium edetate dihydrate (Trilon B) – 0.5 mg, sodium hydrogen phosphate dihydrate – 3.54 mg, potassium dihydrogen phosphate – 3.63 mg, sodium chloride – 9 mg, water for injections – up to 1 ml.
10 ml – dropper bottles (1) – cardboard packs.
Nasal drops as a colorless, clear or light yellow liquid.
| 1 ml | |
| Xylometazoline hydrochloride | 0.5 mg |
Excipients : benzalkonium chloride – 0.15 mg, disodium edetate dihydrate (Trilon B) – 0.5 mg, sodium hydrogen phosphate dihydrate – 3.54 mg, potassium dihydrogen phosphate – 3.63 mg, sodium chloride – 9 mg, water for injections – up to 1 ml.
10 ml – dropper bottles (1) – cardboard packs.
Nasal spray, metered 35 mcg/dose: 15 ml bottle
Nasal spray, metered 140 mcg/dose: 15 ml bottle
Marketing Authorization Holder
Usolye-Sibirskiy Chemical and Pharmaceutical Plant, JSC (Russia)
Dosage Forms
| Sopixil | Nasal spray, metered 35 mcg/dose: 15 ml bottle | |
| Nasal spray, metered 140 mcg/dose: 15 ml bottle |
Dosage Form, Packaging, and Composition
Nasal spray, metered as a colorless, clear or light yellow liquid.
| 1 dose | |
| Xylometazoline hydrochloride | 35 mcg |
Excipients : benzalkonium chloride – 7 mcg, disodium edetate dihydrate (Trilon B) – 7 mcg, sodium hydrogen phosphate dihydrate – 140 mcg, potassium dihydrogen phosphate dihydrate – 140 mcg, sodium chloride – 518 mcg, water for injections – 69.4 mcg.
15 ml – bottles (1) – cardboard packs.
Nasal spray, metered as a colorless, clear or light yellow liquid.
| 1 dose | |
| Xylometazoline hydrochloride | 140 mcg |
Excipients : benzalkonium chloride – 14 mcg, disodium edetate dihydrate (Trilon B) – 70 mcg, sodium hydrogen phosphate dihydrate – 280 mcg, potassium dihydrogen phosphate dihydrate – 280 mcg, sodium chloride – 1020 mcg, water for injections – 138.75 mcg.
15 ml – bottles (1) – cardboard packs.
